Recursion Pharmaceuticals (RXRX) Stock Price

Recursion Pharmaceuticals Price

NASDAQ·CLOSED
4.27
​
Market closed

Revenue has compounded at 87.6% per year over the past 6 years to 74.68 M USD. Recursion Pharmaceuticals's net margin stands at -863.4%, up from -1,780.7% several years earlier. Analysts set a median price target of 5.30 USD, implying 24.1% above the current price. Of 13 analysts, 8 rate the stock a buy — an overall Buy consensus.

Recursion Pharmaceuticals stock price

Access this data via the Eulerpool API

Recursion Pharmaceuticals business model & stock analysis

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 500 full-time employees. The company went IPO on 2021-04-16. The company is focused on utilizing advanced technologies in biology, chemistry, automation, and computer science to discover and design therapeutics. The Company’s platform, Recursion Operating System (OS), is built with diverse technologies and enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The company integrates physical and digital components as iterative loops of atoms and bits of wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of cerebral cavernous malformation (CCM). REC-2282 is developed for the treatment of neurofibromatosis type 2.

Frequently asked questions about Recursion Pharmaceuticals

Analysts currently set an average price target of 5.30 USD for the Recursion Pharmaceuticals stock (median: 5.30 USD), implying +24.1 % versus the latest price. The consensus is based on 13 analyst ratings.

13 analysts currently rate the Recursion Pharmaceuticals stock: 8 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Recursion Pharmaceuticals to generate revenue of 41.19 M USD and earnings per share of -0.89 USD.

Converted at the current exchange rate, the Recursion Pharmaceuticals share trades at 3.81 EUR (4.27 USD).

The Recursion Pharmaceuticals share (RXRX) is listed on 1 stock exchanges, including: NASDAQ (RXRX).

The expected revenue of Recursion Pharmaceuticals is 41.19 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Recursion Pharmaceuticals is -470.39 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Recursion Pharmaceuticals is currently -4.78. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Recursion Pharmaceuticals stock.

The price-to-sales ratio (P/S) of Recursion Pharmaceuticals is currently 54.60. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Recursion Pharmaceuticals stock.

The Eulerpool Quality Score for Recursion Pharmaceuticals is 3/10.

The ISIN of Recursion Pharmaceuticals is US75629V1044. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Recursion Pharmaceuticals is RXRX. The ticker symbol is used to trade Recursion Pharmaceuticals shares on the stock exchange.

Fair ValueTerminal
4.14 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
124,468.33 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Apr 16, 2021
ISIN
US75629V1044
Cusip
75629V104
Market capitalization
2.22 B USDMid Cap
52-Week Range
PEG
-3.65
P/E ratio
P/Ee 2026
-4.78
P/Ee 2027
-4.81
P/Ee 2028
-5.57
P/Ee 2029
-4.60
P/Se
54.60
EV/EBIT
—
P/B Ratio
1.96
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-55.48 %
Last updated Oct 8, 2026, 5:14 AM

Recursion Pharmaceuticals Peer Group

Recursion Pharmaceuticals Ticker

NASDAQ · RXRX

Recursion Pharmaceuticals FIGI

RXRX:US · BBG00PQ4XJ45RXRX:UA · BBG00ZS43G04RXRX:UC · BBG00ZS43G13RXRX:UN · BBG00ZS43G31RXRX:UP · BBG00ZS43G59RXRX:UB · BBG00ZS43G77RXRX:UM · BBG00ZS43G95RXRX:UX · BBG00ZS43GB2RXRX:UD · BBG00ZS43GJ4RXRX:UW · BBG00ZS43GL1RXRX:UF · BBG00ZS43GM0RXRX:VY · BBG00ZS43GN9